COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Pencil Biosciences develops a proprietary modular, non‑CRISPR gene‑editing and modulation platform smaller than Cas‑based systems, engineered for editing and modulation applications across rare diseases and cancer.
